Zenas BioPharma【ZBIO】銘柄情報

Zenas BioPharma Inc (ZBIO) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

19.78

( 6.46% )

買値

13.28

売値

24.92

出来高

2,128,336

18.72 日の範囲 19.88

8.91 52 週間の範囲 44.60

時価総額

1.249B

前日終値

18.58

始値

18.93

時刻

19.99

最終取引時間

財務取引量

US$ 40,689,806

VWAP

19.1181

平均取引量 (3 か月)

US$ 706,647

発行済株式数

63,133,377

配当利回り

PER

-2.24

1 株当たり利益 (EPS)

-8.82

歳入

純利益

-425.15M

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I di... Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

zenasbio.com

本社

Waltham, United States

設立

2026

Zenas BioPharma Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ZBIO. The last closing price for Zenas BioPharma was US$18.58. Over the last year, Zenas BioPharma shares have traded in a share price range of US$ 8.91 to US$ 44.60.

Zenas BioPharma currently has 63,133,377 shares in issue. The market capitalisation of Zenas BioPharma is US$1.25 billion. Zenas BioPharma has a price to earnings ratio (PE ratio) of -2.24.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq:...

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results...

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE...

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D...

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq:...

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.71	9.46319867183	18.07	20.87	17.53	687240	18.87938753	CS
4	0.43	2.22222222222	19.35	20.87	16.77	550350	18.43068649	CS
12	-2.14	-9.76277372263	21.92	22.76	16.41	664652	19.3551873	CS
26	-16.86	-46.0152838428	36.64	44.6	13.5	772383	21.04826519	CS
52	10.1	104.338842975	9.68	44.6	8.91	536222	22.33100222	CS
156	9.7596	97.3973094886	10.0204	44.6	5.83	236741	19.63277441	CS
260	9.7596	97.3973094886	10.0204	44.6	5.83	141591	19.63277441	CS

ZBIO - Frequently Asked Questions (FAQ)

What is the current Zenas BioPharma Inc share price?

The current share price of Zenas BioPharma Inc is US$ 19.78

How many Zenas BioPharma Inc shares are in issue?

Zenas BioPharma Inc has 63,133,377 shares in issue

What is the market cap of Zenas BioPharma Inc?

The market capitalisation of Zenas BioPharma Inc is USD 1.25B

What is the 1 year trading range for Zenas BioPharma Inc share price?

Zenas BioPharma Inc has traded in the range of US$ 8.91 to US$ 44.60 during the past year

What is the PE ratio of Zenas BioPharma Inc?

The price to earnings ratio of Zenas BioPharma Inc is -2.24

What is the registered address of Zenas BioPharma Inc?

The registered address for Zenas BioPharma Inc is 852 Winter Street, Waltham, Massachusetts, 02451

What is the Zenas BioPharma Inc website address?

The website address for Zenas BioPharma Inc is zenasbio.com

Which industry sector does Zenas BioPharma Inc operate in?

Zenas BioPharma Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Zenas BioPharma Inc (ZBIO)

Zenas BioPharma Inc (ZBIO) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Zenas BioPharma Inc について

ZBIO 最新ニュース

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

ZBIO - Frequently Asked Questions (FAQ)

ZBIO 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する